blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1597379

EP1597379 - ENDOMANNOSIDASES IN THE MODIFICATION OF GLYCOPROTEINS IN EUKARYOTES [Right-click to bookmark this link]
StatusThe patent has been limited
Status updated on  21.05.2021
Database last updated on 15.07.2024
Most recent event   Tooltip21.05.2021(Expected) limited patent specificationpublished on 23.06.2021  [2021/25]
Applicant(s)For all designated states
GlycoFi, Inc.
21 Lafayette Street, Suite 200
Lebanon, NH 03766 / US
[2021/25]
Former [2016/31]For all designated states
GlycoFi, Inc.
21 Lafayette Street, Suite 200
Lebanon, NH 03766 / US
Former [2009/14]For all designated states
GlycoFi, Inc.
21 Lafayette Street, Suite 200
Lebanon NH 03766 / US
Former [2006/06]For all designated states
GlycoFi, Inc.
21 Lafayette Street, Suite 200 Lebanon
New Hampshire 03766 / US
Former [2005/47]For all designated states
Hamilton, Stephen R.
11 Rocky Hill Road, 211
Enfield, NH 03748 / US
Inventor(s)01 / Hamilton, Stephen R.
11 Rocky Hill road, 211
Enfield, NH 03748 / US
 [2006/06]
Former [2005/47]01 / see applicant
...
Representative(s)Horgan, James Michael Frederic
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
[2021/25]
Former [2016/31]Horgan, James Michael Frederic
Merck Sharp & Dohme Limited
Hertford Road
Hoddesdon, Herts. EN11 9BU / GB
Former [2011/07]Jaenichen, Hans-Rainer
Vossius & Partner Postfach 86 07 67
81634 München / DE
Former [2009/28]Horgan, James Michael Frederic, et al
Merck & Co., Inc. European Patent Department Merck Sharpe & Dohme Limited Hertford Road Hoddesdon
Hertfordshire EN11 9BU / GB
Former [2009/07]Horgan, James Michael Frederic, et al
Merck Sharp & Dohme Limited European Patent Department Hertford Road
Hoddesdon, Herts. EN11 9BU / GB
Former [2008/35]Vossius & Partner
Siebertstrasse 3
81675 München / DE
Former [2005/47]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date04713369.920.02.2004
[2005/47]
WO2004US05131
Priority number, dateUS2003037187720.02.2003         Original published format: US 371877
US2003069524327.10.2003         Original published format: US 695243
[2005/47]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2004074497
Date:02.09.2004
Language:EN
[2004/36]
Type: A2 Application without search report 
No.:EP1597379
Date:23.11.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 02.09.2004 takes the place of the publication of the European patent application.
[2005/47]
Type: B1 Patent specification 
No.:EP1597379
Date:01.04.2009
Language:EN
[2009/14]
Type: B2 New European patent specification 
No.:EP1597379
Date:03.08.2016
Language:EN
[2016/31]
Type: B3 Limited patent 
No.:EP1597379
Date:23.06.2021
Language:EN
[2021/25]
Search report(s)International search report - published on:EP02.12.2004
ClassificationIPC:C12P21/00, C12N9/24, C12N5/10, C12N15/81
[2005/47]
CPC:
C12P21/005 (EP,US); C12N9/1051 (EP,US); C12N9/2488 (EP,US);
C12Y302/0113 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2016/31]
Former [2005/47]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:ENDOMANNOSIDASEN ZUR MODIFZIERUNG DER GLYKOPROTEINE IN EUKARYOTEN[2005/47]
English:ENDOMANNOSIDASES IN THE MODIFICATION OF GLYCOPROTEINS IN EUKARYOTES[2005/47]
French:ENDOMANNOSIDASES DANS LA MODIFICATION DE GLYCOPROTEINES D'EUKARYOTES[2005/47]
Entry into regional phase20.09.2005National basic fee paid 
20.09.2005Designation fee(s) paid 
20.09.2005Examination fee paid 
Examination procedure20.09.2005Amendment by applicant (claims and/or description)
20.09.2005Examination requested  [2005/47]
14.03.2006Despatch of a communication from the examining division (Time limit: M04)
24.07.2006Reply to a communication from the examining division
26.09.2006Despatch of a communication from the examining division (Time limit: M06)
20.03.2007Reply to a communication from the examining division
12.06.2007Despatch of a communication from the examining division (Time limit: M02)
22.08.2007Reply to a communication from the examining division
01.09.2008Communication of intention to grant the patent
29.12.2008Fee for grant paid
29.12.2008Fee for publishing/printing paid
Opposition(s)Opponent(s)01  30.12.2009  04.02.2010  ADMISSIBLE
Novartis AG
Lichtstrasse 35
CH - 4002 Basel / CH
Opponent's representative
Plasseraud IP
104 Rue de Richelieu
CS92104
75080 Paris Cedex 02 / FR
 [N/P]
Former [2012/36]
Opponent(s)01  30.12.2009  04.02.2010  ADMISSIBLE
Novartis AG
Lichtstrasse 35
CH - 4002 Basel / CH
Opponent's representative
Cabinet Plasseraud
52, rue de la Victoire
75440 Paris Cedex 09 / FR
Former [2011/34]
Opponent(s)01  30.12.2009  04.02.2010  ADMISSIBLE
Novartis AG
Lichtstrasse 35
CH - 4002 Basel / CH
Opponent's representative
Bourgarel, Denis Jacques Marie
Cabinet Plasseraud 52, rue de la Victoire
FR-75440 Paris Cedex 09 / FR
Former [2010/07]
Opponent(s)01  30.12.2009   
Novartis AG
Lichtstrasse 35
CH - 4002 Basel / CH
Opponent's representative
Breuer, Markus
Breuer & Müller Partnerschaft Patentanwälte Heimeranstrasse 35
80339 München / DE
15.02.2010Invitation to proprietor to file observations on the notice of opposition
25.08.2010Reply of patent proprietor to notice(s) of opposition
20.09.2011Date of oral proceedings
22.12.2011Despatch of minutes of oral proceedings
23.12.2011Despatch of interlocutory decision in opposition
13.01.2016Legal effect of interlocutory decision in opposition
29.02.2016Despatch of communication that the patent will be maintained as amended
20.06.2016Fee for printing new specification paid
Appeal following opposition15.02.2012Appeal received No.  T0465/12
02.05.2012Statement of grounds filed
13.01.2016Result of appeal procedure: appeal of the opponent withdrawn
Limitations:01.10.2020Date of receipt of request for limitation
 admissible
18.12.2020Communication of intention to limit the patent
17.05.2021Fee for printing patent specification after limitation
11.11.2020Despatch of a communication from the examining division (Time limit: M02)
24.11.2020Reply to a communication from the examining division
Fees paidRenewal fee
28.02.2006Renewal fee patent year 03
28.02.2007Renewal fee patent year 04
08.02.2008Renewal fee patent year 05
13.02.2009Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT01.04.2009
BE01.04.2009
CY01.04.2009
CZ01.04.2009
DK01.04.2009
EE01.04.2009
FI01.04.2009
IT01.04.2009
NL01.04.2009
RO01.04.2009
SI01.04.2009
SK01.04.2009
TR01.04.2009
BG01.07.2009
SE01.07.2009
GR02.07.2009
ES12.07.2009
PT02.09.2009
HU02.10.2009
IE20.02.2010
LU20.02.2010
MC01.03.2010
CH29.02.2016
LI29.02.2016
[2016/46]
Former [2015/21]AT01.04.2009
BE01.04.2009
CY01.04.2009
CZ01.04.2009
DK01.04.2009
EE01.04.2009
FI01.04.2009
IT01.04.2009
NL01.04.2009
RO01.04.2009
SI01.04.2009
SK01.04.2009
TR01.04.2009
BG01.07.2009
SE01.07.2009
GR02.07.2009
ES12.07.2009
PT02.09.2009
HU02.10.2009
IE20.02.2010
LU20.02.2010
MC01.03.2010
Former [2011/14]AT01.04.2009
BE01.04.2009
CZ01.04.2009
DK01.04.2009
EE01.04.2009
FI01.04.2009
IT01.04.2009
NL01.04.2009
RO01.04.2009
SI01.04.2009
SK01.04.2009
BG01.07.2009
SE01.07.2009
GR02.07.2009
ES12.07.2009
PT02.09.2009
IE20.02.2010
MC01.03.2010
Former [2011/07]AT01.04.2009
BE01.04.2009
CZ01.04.2009
DK01.04.2009
EE01.04.2009
FI01.04.2009
NL01.04.2009
RO01.04.2009
SI01.04.2009
SK01.04.2009
BG01.07.2009
SE01.07.2009
GR02.07.2009
ES12.07.2009
PT02.09.2009
IE20.02.2010
MC01.03.2010
Former [2010/46]AT01.04.2009
BE01.04.2009
CZ01.04.2009
DK01.04.2009
EE01.04.2009
FI01.04.2009
NL01.04.2009
RO01.04.2009
SI01.04.2009
SK01.04.2009
BG01.07.2009
SE01.07.2009
GR02.07.2009
ES12.07.2009
PT02.09.2009
MC01.03.2010
Former [2010/18]AT01.04.2009
BE01.04.2009
CZ01.04.2009
DK01.04.2009
EE01.04.2009
FI01.04.2009
NL01.04.2009
RO01.04.2009
SI01.04.2009
SK01.04.2009
BG01.07.2009
SE01.07.2009
ES12.07.2009
PT02.09.2009
Former [2010/10]AT01.04.2009
BE01.04.2009
CZ01.04.2009
DK01.04.2009
EE01.04.2009
FI01.04.2009
NL01.04.2009
RO01.04.2009
SI01.04.2009
SK01.04.2009
SE01.07.2009
ES12.07.2009
PT02.09.2009
Former [2010/09]AT01.04.2009
CZ01.04.2009
DK01.04.2009
EE01.04.2009
FI01.04.2009
NL01.04.2009
RO01.04.2009
SI01.04.2009
SE01.07.2009
ES12.07.2009
PT02.09.2009
Former [2009/52]AT01.04.2009
EE01.04.2009
FI01.04.2009
NL01.04.2009
SI01.04.2009
SE01.07.2009
ES12.07.2009
PT02.09.2009
Former [2009/50]AT01.04.2009
EE01.04.2009
FI01.04.2009
NL01.04.2009
SI01.04.2009
ES12.07.2009
PT02.09.2009
Former [2009/46]SI01.04.2009
ES12.07.2009
Former [2009/36]SI01.04.2009
Cited inInternational search[X]WO0136432  (HUMAN GENOME SCIENCES INC [US], et al) [X] 1-10,14,15 * sequence 14 *;
 [X]WO0160860  (MILLENNIUM PREDICTIVE MEDICINE [US]) [X] 1-10,14,15 * cDNA 29377 *;
 [A]WO0200856  (FLANDERS INTERUNIVERSITY INST [BE]);
 [A]EP1211310  (KIRIN BREWERY [JP], et al) [A] * page 12, lines 44,45 *;
 [X]WO02097060  (INCYTE GENOMICS INC [US], et al) [X] 1-10,14,15 * CHOP-5 protein *;
 [PX]WO03025148  (HYSEQ INC [US], et al) [PX] 1-10,14,15 * sequence 155 *;
 [X]  - SPIRO MARY JANE ET AL, "Molecular cloning and expression of rat liver endo-alpha-mannosidase, an N-linked oligosaccharide processing enzyme", JOURNAL OF BIOLOGICAL CHEMISTRY, (19971114), vol. 272, no. 46, ISSN 0021-9258, pages 29356 - 29363, XP002293369 [X] 1-15 * page 29361, column 2, paragraph L; figures 2,5 *

DOI:   http://dx.doi.org/10.1074/jbc.272.46.29356
 [X]  - CARNINCI, P. ET AL, "Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4932703L02 product:ENDO-ALPHA-D-MANNOSIDASE homolog [Rattus norvegicus], full insert sequence.", GENBANK, (20021205), XP002293371 [X] 1-10,14,15 * the whole document *
 [L]  - TANG ET AL, "Novel human protein #155", GSP, DERWENT, (20040415), Database accession no. ADI21180, XP002293372 [L] * Protein encoded by Seq Id no 155 from WO03025148; column A *
 [L]  - TANG ET AL., "Novel human protein cDNA #155", GSN, DERWENT, (20040415), Database accession no. ADI21896, XP002293373 [L] * Nucleic acid sequence of cDNA #155 from WO03025148; column A *
 [L]  - SWARNAKAR ET AL., "Carbohydrate-associated protein (CHOP)-5.", GSP, DERWENT, (20030416), Database accession no. AAG79783, XP002293374 [L] * CHOP-5 protein from WO02097060; column A *
 [L]  - SCHLEGEL ET AL, "Human prostate expression marker cDNA 29377", GSN, DERWENT, (20020916), Database accession no. ABV29386, XP002293375 [L] * Sequence data from WO0160860; column A *
 [A]  - SPIRO ROBERT G, "Glucose residues as key determinants in the biosynthesis and quality control of glycoproteins with N-linked oligosaccharides", JOURNAL OF BIOLOGICAL CHEMISTRY, (200011), vol. 275, no. 46, ISSN 0021-9258, pages 35657 - 35660, XP002293370

DOI:   http://dx.doi.org/10.1074/jbc.R000022200
Examination   - WENG SHUAI; SPIRO ROBERT G, "Evaluation of the early processing routes of N-linked oligosaccharides of glycoproteins through the characterization of Man-8GlcNAc-2 isomers: Evidence that endomannosidase functions in vivo in the absence of a glucosidase blockade", GLYCOBIOLOGY, (1996), vol. 6, no. 8, pages 861 - 868, XP000952947

DOI:   http://dx.doi.org/10.1093/glycob/6.8.861
OppositionWO9816651
 WO0200856
    - SPIRO R.G., "Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds", GLYCOBIOLOGY, (2002), vol. 12, no. 4, doi:doi:10.1093/glycob/12.4.43R, pages 43R - 56R, XP008034331

DOI:   http://dx.doi.org/10.1093/glycob/12.4.43R
    - BAUSE E. ET AL, "Purification and Enzymatic Properties of Endo-× 1,2-Mannosidase from Pig Liver Involved in Oligosaccharide Processing", BIOL. CHEM., (199610), vol. 377, pages 639 - 646
    - HIRAIZUMI S. ET AL, "Ligand Affinity Chromatographic Purification of Rat Liver Golgi Endomannosidase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (19940218), vol. 269, no. 7, pages 4697 - 4700
    - LUBAS W.A. ET AL, "Golgi Endo-x-D-mannosidase from Rat Liver, a Novel N-Linked Carbohydrate Unit Processing Enzyme", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (1987), vol. 262, no. 8, pages 3775 - 3781
    - DNA sequence GI: 20547442; NCBI Reference Sequence XP_113472.1; hypothetical protein FLJ12838 (homo sapiens)
    - Protein sequence GI: 18031878; GenBank protein ID AAL07306.1; mandaselin short form (homo sapiens)
    - DNA sequence GI:31873297; GenBank BX537398.1; homo sapiens mRNA;cDNA DKFZp686024118
    - DNA sequence GI:34365158; GenBank BX640869.1; homo sapiens mRNA;cDNA DKFZp686H2266
    - Email correspondence between the opponent and the database provider responsible for public access to sequence information of the two clones as disclosed in BM27and BM28
    - SPIRO R.G., "Glucose Residues as Key Determinants in the Biosynthesis and Quality Control of Glycoproteins with N-Linked Oligosaccharides", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (20001117), vol. 275, no. 46, doi:doi:10.1074/jbc.R000022200, pages 3557 - 35660, XP002293370

DOI:   http://dx.doi.org/10.1074/jbc.R000022200
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.